STB-C017

STB-C017 is a **small-molecule, orally available dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase** being developed by **Syntekabio** for **advanced solid tumors**. It was described as a novel kynurenine-pathway regulator derived using deep learning technology that inhibits both IDO1 and TDO in enzymatic and cellular assays, with the intended effect of reducing kynurenine-mediated immunosuppression in the tumor microenvironment, restoring T-cell activity, and potentially enhancing response to immune checkpoint blockade. Based on the provided context, the program appears to be at the **preclinical** stage.